Medioresinol(Medioresinol) - 药物靶点：PGC-1α_在研适应症：缺血性卒中_专利_临床

概要

基本信息

药物类型

小分子化药

别名

MDN、Medioresinol

靶点

PGC-1α

作用方式

激动剂

作用机制

PGC-1α agonists(Peroxisome proliferator-activated receptor gamma coactivator 1-alpha agonists)

治疗领域

神经系统疾病心血管疾病

在研适应症

缺血性卒中

非在研适应症-

原研机构

中国药科大学

在研机构

中国药科大学

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

结构/序列

分子式C21H24O7

InChIKeyVJOBNGRIBLNUKN-BMHXQBNDSA-N

CAS号40957-99-1

关联

100 项与 Medioresinol 相关的临床结果

登录后查看更多信息

100 项与 Medioresinol 相关的转化医学

登录后查看更多信息

100 项与 Medioresinol 相关的专利（医药）

登录后查看更多信息

340

项与 Medioresinol 相关的文献（医药）

2025-10-01·BIOCHEMICAL SYSTEMATICS AND ECOLOGY

Chemical constituents from the stems of Daphniphyllum angustifolium Hutch. and their chemotaxonomic significance

作者: Wei, Yu-Bin ; Zhang, Heng-Gang ; Zhang, Lan-Chun ; Li, Xiao-Hong ; Mohamed, Khalid-Hassan ; Huang, Xiao-Juan ; Ding, Cai-Feng ; Yin, Chang-Qin ; Yu, Hao-Fei

The phytochem. investigation of the stems of Daphniphyllum angustifolium resulted in the isolation of sixteen known compounds (1-16).This collection included six phenolic compounds (1-6), one sterol (7), one triterpene (8), and eight lignans (9-16).Among them, fifteen compounds (1-6, 8-16) were identified for the first time within the Daphniphyllaceae family.The isolated compounds underwent in vitro testing for antibacterial activity against three bacterial strains, including Bacillus subtilis, Staphylococcus aureus, and Escherichia coli.Compound 15 exhibited significant antimicrobial activity against these bacteria.The chemotaxonomic significance of the isolated compounds from the D.angustifolium is discussed in detail.

2025-10-01·VETERINARY SURGERY

Saline‐based modified del Nido cardioplegia versus multidose St. Thomas cardioplegia in canine mitral valve repair: A randomized controlled trial

Article

作者: Chen, Ayaka ; Uechi, Masami ; Sugiya, Hiroshi ; Nishiyama, Masako ; Nii, Yasuyuki ; Furusato, Shimon ; Kurogochi, Kentaro ; Takahashi, Arane

Abstract:

Objective:

To compare the utility of a saline‐based modified del Nido (mDN) cardioplegia solution with a conventional institutional technique (multidose St. Thomas blood cardioplegia) for mitral valve repair (MVR) in dogs.

Study design:

Prospective, randomized, open‐label trial.

Animals:

Forty client‐owned dogs with myxomatous mitral valve disease (stage B2 and C) eligible for MVR were divided into control and modified mDN groups.

Methods:

Cardioplegia was induced in the control group using 50% blood containing St. Thomas solution every 10 min. In the mDN group, a cardioplegia solution containing 20% blood was administered once or when required. As the primary outcome, serum cardiac troponin I levels were compared 12 h postoperatively between the groups. The other clinical findings were evaluated as secondary outcomes.

Results:

Troponin levels 12 h after surgery were a median of 27.8 ng/mL (interquartile range, 15.1–43.2) in the control group and 19.4 ng/mL (15.2–33.6) in the mDN group (p = .478). The sinus rhythm recovery time following aortic cross‐clamp removal was 362 s (103–995) in the control group and 60 s (44–605) in the mDN group (p = .027). The total amount of crystalloid cardioplegia solution required was 12.6 mL/kg (11.3–15.0) in the control group and 23.6 mL/kg (18.0–35.1) in the mDN group (p < .001).

Conclusion:

Cardiac troponin I levels did not show differences between the groups. The saline‐based mDN cardioplegia facilitated earlier sinus rhythm recovery.

Clinical significance:

Saline‐based mDN cardioplegia may be a viable alternative for canine MVR.

2025-10-01·Annals of Cardiac Anaesthesia

Modified Del Nido Versus Custodiol® Cardioplegia for Myocardial Protection in Adult Patients Undergoing Cardiac Surgery; A Prospective Randomized Double-Blinded Clinical Trial

Article

作者: Abdelhady, Mahdy A. ; Goda, Abeer S. ; Hassan, Alyaa A. S. Mohammed ; Sayed Gomaa, Mohamed S. ; Hamed, Mohamed A.

Background::

Cardioplegia is essential for myocardial protection. Modified Del Nido and Custodiol® cardioplegia have been successfully used; however, a limited number of clinical trials compared both solutions. Our objective was to evaluate the effectiveness of Modified Del Nido cardioplegia against Custodiol® in protecting the myocardium in adult patients having open heart surgery.

Methods::

In this prospective randomized double-blinded clinical trial, fifty-eight adult patients registered for elective open heart surgery at Fayoum University hospitals, Fayoum, Egypt, between February 2022 and November 2023, have enrolled. Patients were randomized to receive either a Modified Del Nido cardioplegia solution (MDN group) (n = 29) or Custodiol® cardioplegia (C group) (n = 29). The primary outcome was Troponin I (µg/L) measured 24 h after surgery.

Results::

Both groups had comparable demographics. Troponin I was much lower in the MDN group (median = 2.9, IQR = 2.7-3.2) than in the C group (median = 3.6, IQR = 3.1-4.1) 24 h after surgery. Similarly, there were substantial differences in CK-MB between the two groups 24 h postoperatively. The MDN group had better results in terms of time taken for cardiac arrest, the incidence of ventricular fibrillation upon cross-removal, and the percentage of patients requiring inotropes. The MDN group shows notably reduced hospital length of stay (LOS), intensive care unit length of stay (ICU LOS), and weaning from mechanical ventilation times.

Conclusions::

Adult cardiac surgery may be performed safely and successfully using Modified Del Nido cardioplegia in comparison to Custodiol® cardioplegia.

100 项与 Medioresinol 相关的药物交易

登录后查看更多信息